Telatinib, aslo known as BAY 57-9352, is a potent and orally active VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Telatinib treatment was well tolerated. The observed single agent antitumor activity in heavily pretreated CRC patients was limited. Pharmacodynamic results are suggestive for the biological activity of telatinib justifying a further evaluation of telatinib bid in combination with standard chemotherapy regimens in CRC patients.
Related Prodcuts:
Fidaxomicin; Marbofloxacin; CP-466722; TTP 22; D-64131; M344; CHIR-124; Reversine; Pralatrexate; XL228; VE-822; RI-1; SRPIN340; XL888; Rigosertib; APY29; NMS-873; PF-03758309; Tanespimycin; ISCK03